This HTML5 document contains 60 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n17http://www.rxlist.com/acetyl-l-carnitine/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
foafhttp://xmlns.com/foaf/0.1/
n13http://linked.opendata.cz/resource/drugbank/mixture/
n7http://linked.opendata.cz/resource/drugbank/drug/DB08842/identifier/chebi/
n15http://bio2rdf.org/drugbank:
n12http://linked.opendata.cz/resource/drugbank/drug/DB08842/identifier/wikipedia/
admshttp://www.w3.org/ns/adms#
n11http://linked.opendata.cz/resource/drugbank/drug/DB08842/identifier/kegg-compound/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n8http://linked.opendata.cz/resource/drugbank/drug/DB08842/identifier/drugbank/
xsdhhttp://www.w3.org/2001/XMLSchema#
n10http://linked.opendata.cz/resource/atc/
n9http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB08842
rdf:type
n3:Drug
n3:description
Acetylcarnitine is an investigational drug in the United states, Italy, United Kingdom, China, Israel, and Norway, and it is approved in Italy, Portugal, Argentina, Chile, Philippines, Australia, and India. Acetylcarnitine can be synthesized, but it is also naturally found in adequate amounts in healthy humans. In human plasma and tissues, acetylcarnitine is the most predominant acylated ester of carnitine, which is an amino acid derivative that is made in the kidney, liver, and brain from lysine and methionine. The main role of acetylcarnitine is to help transport fatty acids into the mitochondrial matrix where fatty acid metabolism occurs.
n3:generalReferences
# Martindale: The Complete Drug Reference. # Vermeulen RC, Scholte HR: Exploratory open label, randomized study of acetyl- and propionylcarnitine in chronic fatigue syndrome. Psychosom Med. 2004 Mar-Apr;66(2):276-82. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15039515 # Ilias I, Manoli I, Blackman MR, Gold PW, Alesci S: L-Carnitine and acetyl-L-carnitine in the treatment of complications associated with HIV infection and antiretroviral therapy. Mitochondrion. 2004 Jul;4(2-3):163-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16120381 # The Merck Index. # Salvioli G, Neri M: L-acetylcarnitine treatment of mental decline in the elderly. Drugs Exp Clin Res. 1994;20(4):169-76. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/7813389 # Rebouche CJ: Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism. Ann N Y Acad Sci. 2004 Nov;1033:30-41. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15591001 # Virmani A, Binienda Z: Role of carnitine esters in brain neuropathology. Mol Aspects Med. 2004 Oct-Dec;25(5-6):533-49. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15363640 # Giancaterini A, De Gaetano A, Mingrone G, Gniuli D, Liverani E, Capristo E, Greco AV: Acetyl-L-carnitine infusion increases glucose disposal in type 2 diabetic patients. Metabolism. 2000 Jun;49(6):704-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10877193 # Barhwal K, Hota SK, Jain V, Prasad D, Singh SB, Ilavazhagan G: Acetyl-l-carnitine (ALCAR) prevents hypobaric hypoxia-induced spatial memory impairment through extracellular related kinase-mediated nuclear factor erythroid 2-related factor 2 phosphorylation. Neuroscience. 2009 Jun 30;161(2):501-14. doi: 10.1016/j.neuroscience.2009.02.086. Epub 2009 Mar 24. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19318118 # Wilson AD, Hart A, Brannstrom T, Wiberg M, Terenghi G: Delayed acetyl-L-carnitine administration and its effect on sensory neuronal rescue after peripheral nerve injury. J Plast Reconstr Aesthet Surg. 2007;60(2):114-8. Epub 2006 Jul 24. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17223507 # Ruggenenti P, Cattaneo D, Loriga G, Ledda F, Motterlini N, Gherardi G, Orisio S, Remuzzi G: Ameliorating hypertension and insulin resistance in subjects at increased cardiovascular risk: effects of acetyl-L-carnitine therapy. Hypertension. 2009 Sep;54(3):567-74. doi: 10.1161/HYPERTENSIONAHA.109.132522. Epub 2009 Jul 20. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19620516
n3:group
approved investigational
n3:indication
Acetylcarnitine is not approved for any indication in the United states and Canada, but it is approved and indicated in Italy for cerebrovascular disorders, mental function disorders, peripheral nerve disorders, diabetic neuropathy, and nutritional supplementation; Portugal for mental function disorders; Argentina for cerebral vasculopathy, nutritional supplementation, and peripheral neuropathy; Chile for dementia; Philippines for cerebrovascular disorders and mental function disorders; Australia for nutritional supplementation; and India for nutritional supplementation to increase sperm count. Acetylcarnitine also has several potential therapeutic indications for which it is still being investigated: in Norway, acetylcarnitine is in a phase IV trial for prophylactic treatment of migraines; in Italy acetylcarnitine is in a phase II trial for use in patients with type 2 Diabetes Mellitus, a phase III trial for alleviating fatigue in patients with chronic hepatitis C, and for use in patients with Minimal Hepatic Encephalopathy; in the United States acetylcarnitine is in a phase II trial for the neurodegenerative disorder Progressive Supranuclear Palsy, a phase II and III trial for reducing peripheral neuropathy in cancer patients as an adjunct to chemotherapy, a phase I and II trial for treating patients in septic shock, a phase II trial for bipolar depression, a phase II trial to reduce oxidative stress in patients with Sickle Cell disease, a phase I and II trial for chronic fatigue syndrome, and a study for preventing nerve damage in HIV patients; in China acetylcarnitine is in a phase III trial for reducing peripheral neuropathy in cancer patients as an adjunct to chemotherapy; in the United Kingdom acetylcarnitine is being investigated for preventing nerve damage in HIV patients; and in Israel acetylcarnitine is being studied for the treatment of male infertility.
owl:sameAs
n15:DB08842
dcterms:title
Acetylcarnitine
adms:identifier
n7:57589 n8:DB08842 n11:C02571 n12:Acetylcarnitine
n3:mechanismOfAction
The mechanisms of action of acetylcarnitine have not been fully elucidated, but it seems that the main role of acetylcarnitine is to donate an acetyl group during fatty acid metabolism to help transport fatty acids, such as acetyl CoA, into the mitochondrial matrix where fatty acid metabolism occurs. Additionally several studies have found that separate from its metabolic role, acetylcarnitine has neuromodulatory, neurotrophic, and neuroprotective effects that most likely are involved in its positive effects in neurological diseases. In its role in treating male infertility, acetylcarnitine increases the active movement of sperm cells. One study has also mentioned a role for acetylcarnitine as an antioxidant. The study found that through the receptor, tyrosine kinase A, acetylcarnitine was able to decrease the production of free radicals, peroxidation of lipids, and oxidation of proteins as well as decrease glutathione levels and increase thioredoxin.
n3:routeOfElimination
Acetylcarnitine is eliminated in a similar manner as L-carnitine. Both of which are eliminated by the kidneys and involve tubular secretion.
n3:synonym
O-Acetylcarnitine O-acetyl-L-carnitine acetyl-L-carnitine
n3:mixture
n13:271B5869-363D-11E5-9242-09173F13E4C5 n13:271B586A-363D-11E5-9242-09173F13E4C5 n13:271B5868-363D-11E5-9242-09173F13E4C5 n13:271B586D-363D-11E5-9242-09173F13E4C5 n13:271B586E-363D-11E5-9242-09173F13E4C5 n13:271B586B-363D-11E5-9242-09173F13E4C5 n13:271B586F-363D-11E5-9242-09173F13E4C5 n13:271B586C-363D-11E5-9242-09173F13E4C5
n3:synthesisReference
Gu, Heng-da; Shi, Shuang; Yang, Ying; Shi, Zhao-xin; Yu, Zhan-long. Synthesis of acetyl-L-carnitine by direct acylation method. Shenyang Huagong Xueyuan Xuebao (2006), 20(2), 154-155, 160.
foaf:page
n17:supplements.htm
n3:IUPAC-Name
n4:271B5874-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B587A-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5879-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5876-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5877-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5878-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B588A-363D-11E5-9242-09173F13E4C5 n4:271B5872-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5870-363D-11E5-9242-09173F13E4C5 n4:271B5873-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5871-363D-11E5-9242-09173F13E4C5
n9:hasATCCode
n10:N06BX12
n3:H-Bond-Acceptor-Count
n4:271B5880-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5881-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B587B-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B587C-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B587E-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B587D-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B587F-363D-11E5-9242-09173F13E4C5
n3:absorption
Acetylcarnitine supplements are absorbed in a similar manner to L-carnitine.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
3040-38-8
n3:category
n3:Bioavailability
n4:271B5886-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5888-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5889-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B588B-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5885-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5884-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5887-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5875-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5882-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5883-363D-11E5-9242-09173F13E4C5